Curated News
By: NewsRamp Editorial Staff
September 11, 2026

Quantum BioPharma's Lucid-MS Featured in BioMedWire MS Editorial

Discuss on Substack
Original Source

TLDR

  • Quantum BioPharma gains an edge with FDA clearance for Lucid-MS, a first-in-class MS drug targeting myelin repair rather than immune suppression.
  • Lucid-MS is a patented compound that protects and rebuilds the myelin sheath, and it is now cleared for a phase 2 trial in MS patients.
  • Quantum BioPharma's Lucid-MS could transform MS treatment by repairing myelin, offering new hope and better lives for patients worldwide.
  • Quantum BioPharma's Lucid-MS may be the first myelin-repair drug tested in people, a novel approach for multiple sclerosis.

Impact - Why it Matters

This news matters because it signals a potential paradigm shift in multiple sclerosis treatment. Current MS therapies primarily focus on immune suppression, which can leave patients vulnerable to infections and may not address the progressive degeneration of myelin. Lucid-MS, with its novel mechanism to protect and rebuild myelin, could offer a much-needed alternative if successful in clinical trials. The FDA’s clearance for a phase 2 trial is a critical step forward, and the BioMedWire editorial brings this innovation to the attention of investors and the MS community. For patients, it represents hope for a therapy that targets the root cause of MS rather than just managing symptoms. For investors, it highlights Quantum BioPharma’s pipeline and the potential of its proprietary technology, which could lead to significant value creation if Lucid-MS proves effective. As the first drug of its kind to be tested in humans for MS, the trial’s outcomes could have far-reaching implications for how the disease is treated, making this a development worth watching closely.

Summary

Quantum BioPharma Ltd. (NASDAQ: QNTM) has secured a prominent spot in a BioMedWire editorial that explores the promise of its lead candidate, Lucid-MS, to overcome the limitations of current multiple sclerosis (MS) treatments. The editorial highlights the U.S. Food and Drug Administration’s clearance for Quantum to launch a phase 2 trial of Lucid-MS, a patented, first-in-class therapy designed to protect and potentially rebuild the myelin sheath rather than suppress the immune system. According to the publication, this would be the first time a drug based on this mechanism is tested in people living with MS, marking a significant milestone for the company and the MS community. The full press release is available at https://ibn.fm/whtAF.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum focuses on the research and development of Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation—the underlying mechanism of MS. Beyond Lucid-MS, Quantum invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, plus royalty payments of 7% of sales until reaching $250 million, after which royalties drop to 3% in perpetuity. The company also retains 100% of rights to develop similar products for pharmaceutical and medical uses. Investors can find the latest updates in the company’s newsroom at https://ibn.fm/QNTM.

The news was disseminated through InvestorWire, a specialized communications platform under the Dynamic Brand Portfolio @ IBN. InvestorWire offers wire-grade press release syndication, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. With a broad reach and a seasoned team, InvestorWire helps private and public companies connect with investors, influencers, consumers, and journalists. Quantum BioPharma’s inclusion in the BioMedWire editorial underscores the potential of its novel approach to MS and its commitment to advancing treatments for unmet medical needs.

Source Statement

This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma's Lucid-MS Featured in BioMedWire MS Editorial

Blockchain registration record for this content